



OPEN

Prognostic value of cardiac biomarkers in COVID-19 infection

Aakash Sheth^{1,2}, Malak Modi^{1,2}, Desiree' Dawson^{1,2} & Paari Dominic¹✉

Multiple Biomarkers have recently been shown to be elevated in COVID-19, a respiratory infection with multi-organ dysfunction; however, information regarding the prognostic value of cardiac biomarkers as it relates to disease severity and cardiac injury are inconsistent. The goal of this meta-analysis was to summarize the evidence regarding the prognostic relevance of cardiac biomarkers from data available in published reports. PubMed, Embase and Web of Science were searched from inception through April 2020 for studies comparing median values of cardiac biomarkers in critically ill versus non-critically ill COVID-19 patients, or patients who died versus those who survived. The weighted mean differences (WMD) and 95% confidence interval (CI) between the groups were calculated for each study and combined using a random effects meta-analysis model. The odds ratio (OR) for mortality based on cardiac injury was combined from studies reporting it. Troponin levels were significantly higher in COVID-19 patients who died or were critically ill versus those who were alive or not critically ill (WMD 0.57, 95% CI 0.43–0.70, $p < 0.001$). Additionally, BNP levels were also significantly higher in patients who died or were critically ill (WMD 0.45, 95% CI – 0.21–0.69, $p < 0.001$). Cardiac injury was independently associated with significantly increased odds of mortality (OR 6.641, 95% CI 1.26–35.1, $p = 0.03$). A significant difference in levels of D-dimer was seen in those who died or were critically ill. CK levels were only significantly higher in those who died versus those who were alive (WMD 0.79, 95% CI 0.25–1.33, $p = 0.004$). Cardiac biomarkers add prognostic value to the determination of the severity of COVID-19 and can predict mortality.

Abbreviations

COVID-19	Coronavirus 2019
WMD	Weighted mean differences
CI	95% Confidence interval
OR	Odds ratio
BNP	Brain natriuretic peptide
CK	Creatine kinase
LDH	Lactate dehydrogenase
CRP	C-reactive protein
IL-6	Interleukin 6
SARS-CoV-2	Severe acute respiratory syndrome coronavirus-2

The Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has affected over 2,402,250 people worldwide and caused 163,097 deaths as of April 21, 2020¹. Lung injury and acute respiratory distress syndrome are the most common presentation of COVID-19, but cardiac injury is another grim consequence of this multisystem viral disease. Evidence of an association between other systemic viral infections such as influenza² and SARS³ and cardiovascular adverse events dates back to the 1930s⁴. Early observational studies in China and reports from The Centers for Disease Control and Prevention (CDC) suggest that patients with pre-existing heart conditions are more likely to develop severe illness from COVID-19⁵. A recent study⁶ suggests that patients in the ICU are three-fold more likely to have pre-existing cardiovascular conditions than non-ICU patients. Conversely, newer evidence implies new onset myocardial injury caused by COVID-19^{7,8}. Possible mechanisms of myocardial injury caused by COVID-19, termed acute COVID-19 cardiovascular syndrome (ACovCS), include heightened myocardial demand in response to the stress of infection, inflammatory cytokines creating a thrombogenic environment as the result of platelet activation and

¹Division of Cardiology, The Department of Medicine and Center of Excellence for Cardiovascular Diseases & Sciences, Louisiana State University Health Sciences Center-Shreveport (LSUHSC-S), 1501 Kings Hwy, Shreveport, LA 71103, USA. ²These authors contributed equally: Aakash Sheth, Malak Modi and Desiree' Dawson. ✉email: pdomi2@lsuhsc.edu




Figure 1. Prisma diagram of literature search and selection.

endothelial dysfunction, and direct myocardial damage^{9,10}. However, current evidence linking myocardial injury as measured by cardiac biomarkers to the severity of disease is conflicting, with a few studies^{11–13} suggesting an association but several others showing a lack of association^{14,15}. Given the discrepancy among these reports, it is prudent to investigate the association of cardiac biomarkers with the severity of disease experienced by and the survival or death of COVID-19 patients. Here we present a meta-analysis of 16 observational studies from China to shed further light on this topic.

Methods

Our meta-analysis was carried out in accordance with the recommendations of the Meta-analysis of Observational Studies in the Epidemiology Group (MOOSE)¹⁶.

Search strategies. We searched MEDLINE/PubMed (1966–2020) on 4/15/2020 using the following keywords: ("covid-19" OR "COVID-19" OR "SARS-CoV-2" OR "coronavirus" AND "19") AND ("Clinical Study" OR "Comparative Study" OR "Evaluation Studies" OR "Meta-Analysis" OR "Multicenter Study" OR "Observational Study" OR "Twin Study" OR "Technical Report" OR "cohort studies" OR "cohort" OR "case-control" OR "cross-sectional" OR "observational" OR "comparative" OR "evaluation"). We also used the 'Related article' feature on PubMed, along with a manual search of references, to identify additional studies. Further, we performed an additional search on Embase and Web of Science, limited to 4/15/2020 and all searches were finalized on 11/10/2020. We reviewed the full text of all relevant articles. English translations, if necessary, were obtained. Titles and abstracts were independently reviewed by three reviewers (AS, DD, and MM) and cross-verified for inclusion. Details of the search strategy are reported in Fig. 1.

Study	Region	Total # Patients	Study design	Time from symptom onset to Death (days)	Time from Admission to Death (days)	Time from Symptom onset to discharge (days)	Time from Admission to Discharge (days)	Troponin	CK	D-Dimer	LDH	NT-pro BNP	Quality Assessment Scale*
Wang D et al., 2020 ¹¹	Wuhan, China	138	Single Center Retrospective Case series	--	--	--	--	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	GOOD
Chen C et al., 2020 ¹²	Wuhan, China	150	Single Center Retrospective Cross sectional	--	--	--	--	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	FAIR
Deng Q et al., 2020 ¹³	Wuhan, China	112	Single Center Retrospective Cohort	23 (15-39)	--	32 (IQR: 22-38)	--	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	GOOD
Huang C et al., 2020 ¹⁴	Wuhan, China	41	Single Center Prospective Cohort	--	--	--	--	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	GOOD
Peng Y et al., 2020 ¹⁵	Wuhan, China	112	Single Center Retrospective Cohort	--	--	--	--	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	POOR
Guo T et al., 2020 ²⁰	Wuhan, China	187	Single Center Retrospective Case series	--	With elevated TrT: 23.2 (8-41)	--	--	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	GOOD
					With cardiac injury: 6.3 (1-16)			<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
					Without cardiac injury: 7.8 (1-23)			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Shi S et al., 2020 ²¹	Wuhan, China	416	Single Center Retrospective Cohort	--	--	--	--	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	GOOD
Ruan Q et al., 2020 ²²	Wuhan, China	150	Multicenter Retrospective Case control	18.4 (5-48)	--	--	--	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	FAIR
Deng Y et al., 2020 ²³	Wuhan, China	225	Multicenter Retrospective Cohort	--	--	--	--	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FAIR
Zhou F et al., 2020 ²⁴	Wuhan, China	191	Multicenter Retrospective Cohort	18.5 (15-22)	--	22 (18-25)	--	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	GOOD
Chen T et al., 2020 ²⁵	Wuhan, China	274	Single Center Retrospective Case series	16 (12-20)	5(3-9.3)	26 (21.8-29)	16 (14-19)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	GOOD
Wu C et al., 2020 ²⁷	Wuhan, China	201	Single Center Retrospective Cohort	--	--	--	--	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	GOOD
Han H et al., 2020 ²⁸	Wuhan, China	213	Single Center Retrospective Cohort	--	--	--	--	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	FAIR
Zheng Y et al., 2020 ²⁹	Chengdu, China	99	Single Center Retrospective Case series	--	--	--	24 (12.82 - 36.82)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	GOOD
Yan Y et al., 2020 ²⁶	Wuhan, China	48	Single Center Retrospective Cohort	--	--	--	10 (6-13)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	GOOD
Wang Y et al., 2020 ²⁵	Wuhan, China	110	Single Center Retrospective Cohort	--	--	--	--	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	FAIR

Table 1. Clinical characteristics and laboratory markers of patients affected by the coronavirus disease 2019 (COVID-19), in the included studies. *Newcastle–Ottawa Quality Assessment Scale. Poor < 4, Fair 5–6, Good > 7.

Inclusion criteria. For the analysis of cardiac biomarker levels in patients with COVID-19. Studies (retrospective and prospective) comparing mean or median troponin and/or BNP in COVID-19 patients who were critically ill versus not critically ill, and those who died versus those who survived, were included. Mean or median levels of other biomarkers included in the studies like CK, D-Dimer, LDH, IL-6, and/or CRP levels in COVID-19 patients were analyzed and compared between patients who were critically ill versus not critically ill, and those who died versus those who survived, only when reported in studies that fit our initial inclusion criteria. Adult respiratory distress syndrome was considered a surrogate for critical illness and studies that compared findings in COVID-19 patients who developed ARDS to patients without ARDS were included. As these were in-hospital outcomes, no specific follow up period was set as an inclusion criteria.

For the analysis of risk of mortality in COVID-19 patients based on cardiac injury. Studies reporting the risk of mortality with COVID-19 based on the presence of cardiac injury by event rates or univariate or multivariate logistic regression analysis were included. Cardiac injury, for the purpose of this meta-analysis, was defined as an increase in Troponin I, Troponin T, or CK MB. For both groups of studies, the timing of the blood draw during the hospitalization was not a pre-specified inclusion criteria.

Exclusion criteria. Studies were excluded if they (i) only gave descriptive statistics of the biomarkers in one group of patients with COVID-19, (ii) were published only in abstract form, (iii) were non-English studies with no English translation, and/or (iv) were studies that reported measures of central tendency in groups other than those under consideration, i.e., died versus survived and critically ill versus not critically ill.

Data extraction and assessment of study quality. For each study included, all data elements reported uniformly across most studies were extracted by two reviewers (AS and MM), cross-verified by a third (DD), and included in Table 1. The quality of each study and the risk of bias were evaluated using the Newcastle–Ottawa Quality Assessment Scale for non-randomized studies¹⁷. The following characteristics were assessed for sources of bias: (1) patient selection including definitions of exposure and representation of the larger population; (2) comparability of study groups and controlling for confounding factors by design or analysis; and (3) assessment and documentation of outcome including duration and loss of follow-up. Studies were graded as ‘poor’ if they met four or fewer of the nine criteria, ‘fair’ if they met five to six criteria, and ‘good’ if they met more than six criteria. For uniformity, all studies, regardless of study design, underwent quality bias assessment using the retrospective cohort scoring tool.

Statistical methods. For the analysis of measures of central tendency of cardiac biomarkers in COVID-19 patients who died or were critically ill, median biomarker values were extracted for patients who died or were critically ill and patients who survived and/or were not critically ill, and the weighted mean differences (WMD) and 95% confidence interval (CI) between these two groups were calculated for each study. For the analysis of the risk of mortality with COVID-19 infection based on cardiac injury, event rates or univariate and multivariate odds ratios (OR) for mortality were extracted. For studies reporting Hazard ratio (HR) only, HR was adopted as the best estimate of OR. OR were transformed logarithmically, then standard error was calculated from Log OR and the corresponding 95% confidence interval (CI). The inverse variance method was used to achieve a weighted estimate of the combined overall effect. For all the analyses, we assessed the results for heterogeneity in our analysis by examining the forest plots and then calculating a Q statistic, which we then compared with the I² index. We considered the presence of significant heterogeneity at the 5% level of significance (for the Q test)

Author	AGE (median)	Male gender, n (%)	Hypertension, n (%)	Diabetes, n (%)	Cardiovascular disease, n (%)	COPD, n (%)
Ruan et al. ²²	57.7	102/150 (68)	53/150 (35)	26/150 (17)	14/150 (9)	3/150 (2)
Deng et al. ²³	54.1	124/225 (55)	59/225 (26)	27/225 (12)	18/225 (8)	25/225 (11)
Huang et al. ¹⁴	49	30/41 (73)	6/41 (15)	8/41 (20)	6/41 (15)	1/41 (2)
Wu et al. ²⁶	52.4	128/201 (64)	38/201 (19)	22/201 (11)	8/201 (4)	NR
Wang et al. ¹¹	56	75/138 (54)	43/138 (31)	14/138 (10)	21/138 (15)	4/138 (3)
Zhou et al. ²⁴	56	119/191 (62)	57/191 (30)	36/191 (19)	15/191 (8)	6/191 (3)
Chen et al. ²⁵	62	171/274 (62)	93/274 (34)	47/274 (17)	22/274 (8)	19/274 (7)
Chen et al. ¹²	58.9	84/150 (56)	50/150 (33)	20/150 (13)	9/150 (6)	NR
Deng et al. ¹³	65	57/112 (51)	36/112 (32)	19/112 (17)	15/112 (13)	4/112 (4)
Guo et al. ²⁰	58.5	91/187 (49)	62/187 (33)	28/187 (15)	21/187 (11)	4/187 (2)
Peng et al. ¹⁵	62	53/112 (47)	92/112 (82)	24/112 (21)	62/112 (55)	NR
Shi et al. ²¹	64	205/416 (49)	129/416 (31)	58/416 (14)	46/416 (11)	12/416 (3)
Han et al. ²⁹	58	26/75 (35)	NR	NR	NR	NR
Wang et al. ²⁸	NR	48/110 (44)	23/110 (21)	15/110 (14)	NR	6/110 (5)
Yan et al. ²⁶	69.4	33/48 (69)	24/48 (50)	48/193 (25)	13/48 (27)	4/48 (8)
Zheng et al. ³⁰	49.4	51/99 (52)	NR	2.5/41 (6)	NR	NR

Table 2. Baseline Demographics of patients with COVID-19. *NR* not reported.

and values of I^2 exceeding 56% as an indicator of significant heterogeneity^{18,19}. We adopted the random effect model to pool WMD or effect sizes. All analyses were performed using Comprehensive Meta-Analysis version 3 (Biostat Inc., Englewood, NJ, USA).

For Meta-regression, we adopted a weighted regression random effect model and carried out a multivariate regression of pre-determined factors using comprehensive meta-analysis version 3. These variables were selected based on traditional factors shown to affect cardiovascular health and on data availability for the majority of the studies included. A two-sided P -value < 0.05 was regarded as significant for all analyses. Data were represented as forest plots, and potential publication bias was assessed with the Egger test and represented graphically with Begg funnel plots of the natural log of the OR versus its standard error.

Results

Sixteen studies with 2667 patients were included in the study. Through the initial database search, 974 studies were investigated for compliance with the inclusion criteria, of which 42 studies were ultimately chosen for consideration. Twenty-six studies were excluded from the meta-analysis for the following reasons: (1) 4 studies were descriptive and only reported biomarkers in all patients and did not compare critical/died versus not critical/alive patients. These studies did not define cardiac injury and did not assess OR for mortality with cardiac injury; (2) 19 studies did not report the biomarkers being studied; (3) 2 studies reported biomarkers based on increased or normal D-dimers; and (4) 1 study did not provide official translation to English. Fifteen studies were retrospective, and thirteen were single center (Table 1). Of the studies that reported time to blood sample collection, the average time reported was at the time of admission to 48 h after admission. Of the studies that reported time to death or discharge, most of the studies reported it as the time from symptom onset to death or discharge. The average time for symptom onset to discharge was 27 days, and from symptom onset to death was 19 days. Two studies did not report median/mean cardiac biomarkers by predetermined patient groups^{20,21}, but reported an OR for mortality based on cardiac injury. 5 studies reported biomarkers based on whether the patients survived or died^{20,22–26}, 9 studies reported them based on whether the patient was critically ill or not^{11–15,27–30}. Baseline demographics and comorbidities of patients included in the studies are shown in Table 2.

Troponin. Twelve studies with a total of 1,715 patients were included for this analysis. Seven of the studies compared critically ill versus not critically ill patients, and the other 5 studies compared levels in dead versus alive patients. Results showed that patients who died or were critically ill had significantly higher troponin levels compared to patients who were alive or were not critically ill (WMD 0.57, 95% CI 0.43–0.70, $p < 0.001$). Sub-group analysis of the studies evaluating patients who died compared to patients who were alive showed that there was a significantly higher troponin level in those who died (WMD 0.61, 95% CI 0.46–0.76, $p < 0.001$). On the other hand, meta-analysis of studies comparing troponin levels in patients who were critically ill to those in patients who were not critically ill showed no difference in troponin levels (WMD 0.28, 95% CI – 0.14–0.69, $p = 0.059$, Fig. 2). The difference between these 2 groups of studies, i.e., studies that compared dead and alive and those that compared critically ill and not critically ill patients, was not significantly different ($p = 0.14$).

The test for heterogeneity for the analysis of the 12 studies was an I^2 of 54.5; therefore, a multivariate meta-regression analysis was performed with age, male gender, diabetes, hypertension, and cardiovascular disease. This analysis showed that hypertension ($p = 0.027$, Supplemental Fig. 2) and cardiovascular disease ($p = 0.001$), (Supplemental Fig. 3), contributed to the differences among studies in the reported troponin levels between the compared groups ($R = 1$). Specifically, with increasing incidence of hypertension, there was a higher WMD in




Figure 2. Forest plot of WMD in troponin between alive and/or not critically ill patients and dead and/or critically ill patients with COVID-19.




Figure 3. Forest plot of WMD in BNP between alive and/or not critically ill patients and dead and/or critically ill patients with COVID-19.

the troponin levels in patients who were dead or critically ill compared to levels in patients who were alive or not critically ill. The incidence of cardiovascular disease in the studies, on the other hand, was inversely related to the WMD of troponin between the groups.

Risk of death based on biomarker proven cardiac injury: we included 4 studies that reported a hazard ratio for death or event rates based on cardiac injury. Of these studies, 1 study used CK-MB without providing a definition²⁷. One study¹⁶ used troponin T and defined cardiac injury as troponin T levels above the 99th percentile upper reference limit. Troponin I levels were used in two studies, and both studies defined cardiac injury as troponin I levels above the 99th percentile upper reference limit^{21,24}.

For the purpose of the meta-analysis, we extracted adjusted effect sizes, when available. In studies that did not report adjusted effect sizes, unadjusted OR was extracted. One study reported number of deaths and total sample size in each group, which was used in the analysis. Our analysis showed that cardiac injury was independently associated with significantly increased odds of mortality (OR 6.641, 95% CI 1.26–35.1, $p=0.03$).

BNP. There were 9 studies with 1305 patients that reported NT-proBNP. Six studies compared critically ill versus not critically ill patients, and the other 3 studies compared results from dead and alive patients. Analysis of these 9 studies did show a significant difference in BNP levels in patients who died or were critically ill compared to levels in those who were alive or were not critically ill (WMD 0.45, 95% CI $-0.21-0.69$, $p < 0.001$). Subgroup analysis showed that there was no significant difference in patients who died compared to patients who were alive (WMD 0.81, 95% CI $-0.33-1.96$, $p=0.17$); however, there was a significant difference seen in patients who were critically ill and those who were not (WMD 0.43, 95% CI $-0.18-0.68$, $p=0.001$) (Fig. 3).

Creatinine kinase (CK). Eight studies with a total of 1,066 patients were included in this analysis. Four of the studies compared critically ill versus not critically ill patients, and the other 4 studies compared CK levels in dead patients versus alive patients. There was no significant difference in the CK levels in patients who died or




Figure 4. Biomarkers in COVID-19 patients. ^aSignificant difference seen in biomarkers in COVID-19 patients who were critically ill. ^bSignificant difference seen in biomarkers in COVID-19 patients who died. *Significant difference seen in biomarkers in COVID-19 patients who died and/or were critically ill. Superscripts: total number of articles in each group. Biomarkers studied: Troponin, BNP, CK, CRP, LDH, D-dimer, IL-6.

were critically ill and those in patients who were alive or were not critically ill (WMD 0.21, 95% CI - 0.05–0.47, $p = 0.12$). Sub-group analysis showed that there was a significantly higher CK level in patients who died (WMD 0.79, 95% CI 0.25–1.33, $p = 0.004$) compared to patients who survived, whereas the patients who were critically ill did not have significantly higher CK levels compared to the patients who were not critically ill (WMD 0.04, 95% CI - 0.26–0.33, $p = 0.82$). (Supplemental Fig. 1) The difference between these 2 groups of studies (studies comparing dead versus alive and those that compared critically ill versus not critically ill patients) was not significantly different.

D-dimer. Nine studies with a total of 1214 patients evaluated D-dimer levels in COVID-19 patients. Six studies compared critically ill versus not critically ill patients, and the other three compared levels from dead patients versus alive patients. Analysis of these nine studies showed that patients who died or were critically ill had significantly higher D-dimer levels compared to patients who were alive or were not critically ill (WMD OR 0.66, 95% CI 0.47–0.85, $p < 0.001$). Sub-group analysis of studies evaluating patients who died compared to patients who were alive showed that there was a significantly higher D-dimer level in those who died (WMD 0.57, 95% CI 0.32–0.82, $p < 0.001$). Similarly, critically ill patients had a significantly higher D-dimer level compared to the patients who were not critically ill (WMD 0.79, 95% CI 0.49–1.08, $p < 0.001$). (Supplemental Fig. 4).

LDH. Nine studies with a total of 1267 patients evaluated LDH levels in COVID-19 patients. Five of the studies compared critically ill versus not critically ill patients, and the other four compared levels from dead patients versus alive patients. Analysis of these eight studies showed that patients who died or were critically ill had significantly higher LDH levels compared to patients who were alive or were not critically ill (WMD 0.58, 95% CI 0.39–0.74, $p < 0.001$). Sub-group analysis showed that there was a significantly higher LDH level in those who died (WMD 1.41, 95% CI - 0.41–2.41, $p = 0.006$) compared to those who were alive, and that critically ill patients had significantly higher LDH levels compared to patients who were not critically ill (WMD 0.54, 95% CI 0.36–0.72, $p < 0.001$). The difference between these two groups of studies, dead versus alive and studies that compared critically ill versus not critically ill patients, was not significantly different. (Supplemental Fig. 5).

Discussion

This meta-analysis summarizes current evidence regarding biomarkers as prognosticators of outcomes in Covid-19 infection and outlines the utility of cardiac biomarkers to predict severe illness and/or death and is unique in that it is the only meta-analysis within the studied time frame that analyzed troponin in critically ill and dead patients as separate subgroups. Our study demonstrates that there exists a statistically significant association between disease severity and cardiac injury. Our analysis showed that troponin and BNP levels were higher among patients who died or were critically ill compared to those in patients who survived or were not critically ill (Fig. 4). When analyzed by sub-groups, we found that levels of troponin and CK were significantly elevated in patients with a fatal outcome compared to those who did not die, but were not significantly different in patients who were critically ill and those who were not (Fig. 4). Prior meta-analyses showed an association between increase in troponin levels in regards to mortality or severe disease (i.e., patients requiring mechanical ventilation,

ICU admission, or those who died); however, a sub-group analysis of the biomarkers was not performed^{31,32}. The results of our meta-analysis are also different from the ones published by Santoso et al. in which they found increased troponin levels in patients who died as well as in patients who were admitted to the ICU or had severe COVID-19 infection. Additionally, these studies only included troponin as the cardiac marker in their analysis as a prognostic indicator^{31–33}. Our sub-group analysis also found that BNP levels were significantly different in critically ill patients compared to those who were not critically ill.

While pre-existing cardiac co-morbidities increase the risk of Acute COVID-19 Cardiovascular Syndrome (ACoVCS)^{34,35}, recent evidence shows that SARS-CoV-2 can cause acute myocarditis-like illness in an otherwise healthy patient³⁶. The mechanism of cardiac injury caused by SARS-CoV-2 is not yet understood, but possible mechanisms include cytokine storm as a result of dysfunctional and uncontrolled immunological response, evidenced by increased levels of d-dimer, IL-6, CRP and LDH^{14,37}, and primary cardiac injury caused by SARS-CoV-2. The first case of acute cardiac injury directly linked to myocardial localization of SARS-CoV-2, demonstrated by endomyocardial biopsy, was reported by Tavazzi et al.³⁸ The viral envelope of SARS-CoV-2 is studded with glycoproteins called Spike proteins composed of two subunits. Subunit S1 has affinity for ACE2 receptors on the cell surface and Subunit S2 fuses with the cell membrane; acting together, these two proteins aid in the endocytosis of the viral particle^{39,40}. Cardiac tissue has a significantly higher expression of ACE2 receptors and is therefore prone to direct cardiac injury in patients with COVID-19^{41,42}.

A recent study done by Liu et al. showed that increased levels of Angiotensin-2 (AT-2) in the plasma of patients infected with COVID-19 showed a linear association with the severity of the disease⁴³. SARS-CoV-2 reduces the expression of ACE2 due to internalization as shown in a study by Oudit et al., which demonstrated a marked decrease in ACE2 expression in the myocardium of mice infected with SARS-CoV-2⁴⁴. ACE2 is responsible for the degradation of AT-2 into Ang 1–7, which is cardioprotective and has anti-inflammatory and anti-fibrotic properties⁴⁵. The loss of ACE2 shifts the balance towards an accumulation of AT-2, which has inflammatory and pro-thrombotic properties. AT-2 promotes vasoconstriction and increases the levels of Plasminogen Activator Inhibitor-1, which plays an active role in thrombogenesis and myocardial infarction⁴⁵. This shift in RAAS axis towards AT-2 could possibly explain high D-dimer levels, a biomarker that showed clearly increased levels in both critically ill patients and patients who died compared to levels in not critically ill and alive patients in our meta-analysis (Fig. 4).

Surprisingly, among the cardiac biomarkers (troponin, CK, and BNP) analyzed in this meta-analysis, only BNP had levels significantly higher in critically ill patients compared to levels in patients who were not critically ill, the levels of CK and troponin were significantly higher in patients who died compared to the levels in those who survived (Fig. 4). Surprisingly, based on our meta-analysis, BNP levels did not differ in patients who died and those who lived. In addition to ventricular stretch, BNP is a known marker for many other conditions, including lung disease, pulmonary hypertension, kidney dysfunction, and excessive cortisol levels. COVID-19 infection causes an assortment of these conditions in the different groups of patients, effectively neutralizing the differences between the groups. Troponin and BNP were both higher in the combined analysis of critically ill and/or dead COVID-19 patients compared to not critically ill and/or alive patients. These results suggest that while there could be minimal changes in troponin in critically ill patients due possibly to non-cardiac reasons, significant elevation in COVID-19 patients may be an indication of direct myocardial injury, which in turn increases the risk of death, thereby making it a crucial tool in predicting death. Unfortunately, not many studies reported the MB isofraction of CK. In addition, the inflammatory biomarkers (IL-6 and CRP; see Supplementary Figs. 6 and 7) and D-dimer levels from the same studies were significantly increased in the critically ill patients and the patients who died compared to levels in the control population, suggesting that it might be difficult to use these biomarkers to differentiate patients who are just critically ill from those at risk of dying. However, the difference in IL-6 (p 0.04) and CRP (p 0.04) levels between patients who died compared to levels in patients who survived was significantly higher than in patients who were critically ill and those who were not (Fig. 4). Finally, LDH was significantly higher in both critically ill patients and patients who died compared to those who had mild illness and those who survived.

Limitations

Our study has several limitations. First, the critical and not critical groups included in our analysis are heterogeneous, i.e., we defined critical as patients who required ICU admission as well as those who developed severe lung injury and ARDS. Similarly, the criteria for ICU admissions may differ from one hospital to another. Second, most studies were conducted in and published from China and therefore the generalizability of this information to other parts of the world and ethnicities is limited. The absence of details regarding the timing of measurement of biomarkers during the hospital stay limits the use of the results as an aid to the ‘predictability’ of death or critical illness. Last, the studies included in the meta-analysis evaluating the risk of mortality with cardiac injury varied in their definitions of cardiac injury.

Data availability

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Received: 3 June 2020; Accepted: 10 February 2021

Published online: 02 March 2021

References

1. WHO. WHO. <https://covid19.who.int/>. Accessed 21 April 2020.

2. Kwong, J. C., Schwartz, K. L. & Campitelli, M. A. Acute myocardial infarction after laboratory-confirmed influenza infection. *N. Engl. J. Med.* **378**(26), 2540–2541. <https://doi.org/10.1056/NEJMc1805679> (2018).
3. Madjid, M., Vela, D., Khalili-Tabrizi, H., Casscells, S. W. & Litovsky, S. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: Clues to the triggering effect of acute infections on acute coronary syndromes. *Tex. Heart Inst. J.* **34**(1), 11–18 (2007).
4. Nunes, B. *et al.* Excess mortality associated with influenza epidemics in Portugal, 1980 to 2004. *PLoS ONE* **6**(6), e20661. <https://doi.org/10.1371/journal.pone.0020661> (2011).
5. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fspecific-groups%2Fhigh-risk-complications.html. Accessed 21 April 2020.
6. Guan, W. J. *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoA2002032> (2020).
7. Bhatraju, P. K. *et al.* Covid-19 in Critically ill patients in the seattle region: Case series. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoA2004500> (2020).
8. Fried, J. A. *et al.* The variety of cardiovascular presentations of COVID-19. *Circulation* <https://doi.org/10.1161/CIRCULATIONAHA.120.047164> (2020).
9. Sala, S. *et al.* Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. *Eur Heart J.* <https://doi.org/10.1093/eurheartj/ehaa286> (2020).
10. Alhobgani, T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. *Ann. Saudi Med.* **36**(1), 78–80. <https://doi.org/10.5144/0256-4947.2016.78> (2016).
11. Wang, D. *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* <https://doi.org/10.1001/jama.2020.1585> (2020).
12. Chen, C., Yan, J. T., Zhou, N., Zhao, J. P. & Wang, D. W. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. *Zhonghua Xin Xue Guan Bing Za Zhi.* **48**, E008. <https://doi.org/10.3760/cma.j.cn112148-20200225-00123> (2020).
13. Deng, Q. *et al.* Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. *Int. J. Cardiol.* <https://doi.org/10.1016/j.ijcard.2020.03.087> (2020).
14. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) (2020).
15. Peng, Y. D. *et al.* Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. *Zhonghua Xin Xue Guan Bing Za Zhi.* **48**, E004. <https://doi.org/10.3760/cma.j.cn112148-20200220-00105> (2020).
16. Stroup, D. F. *et al.* Meta-analysis Of observational studies in epidemiology (MOOSE) group. *JAMA* **283**(15), 2008–2012. <https://doi.org/10.1001/jama.283.15.2008> (2000).
17. Wells, G. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. *Eur. J. Epidemiol.* **1**, 1–21 (2010).
18. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *BMJ* **327**(7414), 557–560. <https://doi.org/10.1136/bmj.327.7414.557> (2003).
19. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **21**(11), 1539–1558. <https://doi.org/10.1002/sim.1186> (2002).
20. Guo, T. *et al.* Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.1017> (2020).
21. Shi, S. *et al.* Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.0950> (2020).
22. Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* <https://doi.org/10.1007/s00134-020-05991-x> (2020).
23. Deng, Y. *et al.* Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: A retrospective study. *Chin. Med. J.* <https://doi.org/10.1097/CM9.0000000000000824> (2020).
24. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* **395**(10229), 1054–1062. [https://doi.org/10.1016/s0140-6736\(20\)30566-3](https://doi.org/10.1016/s0140-6736(20)30566-3) (2020).
25. Chen, T. *et al.* Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* **368**, m1091. <https://doi.org/10.1136/bmj.m1091> (2020).
26. Yan, Y. L. *et al.* Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. *BMJ Open Diabetes Res. Care.* **8**(1), e001343. <https://doi.org/10.1136/bmjdr-2020-001343> (2020).
27. Wu, C. *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* <https://doi.org/10.1001/jamainternmed.2020.0994> (2020).
28. Wang, Y. *et al.* Clinical characteristics of patients with severe pneumonia caused by the SARS-CoV-2 in Wuhan, China. *Respiration.* **99**(8), 649–657. <https://doi.org/10.1159/000507940> (2020).
29. Han, H. *et al.* Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. *J Med Virol.* **92**(7), 819–823. <https://doi.org/10.1002/jmv.25809> (2020).
30. Zheng, Y. *et al.* Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. *J. Clin. Virol.* **127**, 104366. <https://doi.org/10.1016/j.jcv.2020.104366> (2020).
31. Lippi, G., Lavie, C. J. & Sanchis-Gomar, F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. *Prog. Cardiovasc. Dis.* **63**(3), 390–391. <https://doi.org/10.1016/j.pcad.2020.03.001> (2020).
32. Vrsalovic, M. & Vrsalovic, P. A. Cardiac troponins predict mortality in patients with COVID-19: A meta-analysis of adjusted risk estimates. *J. Infect.* **81**(3), e99–e100. <https://doi.org/10.1016/j.jinf.2020.05.022> (2020).
33. Santos, A. *et al.* Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. *Am. J. Emerg. Med.* <https://doi.org/10.1016/j.ajem.2020.04.052> (2020).
34. Garg, S. *et al.* Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019: COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb. Mortal Wkly. Rep.* **69**(15), 458–464. <https://doi.org/10.15585/mmwr.mm6915e3> (2020).
35. Hendren, N. S., Drazner, M. H., Bozkurt, B. & Cooper, L. T. Description and proposed management of the acute COVID-19 cardiovascular syndrome. *Circulation* <https://doi.org/10.1161/CIRCULATIONAHA.120.047349> (2020).
36. Inciardi, R. M. *et al.* Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.1096> (2020).
37. Qin, C. *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciaa248> (2020).
38. Tavazzi, G. *et al.* Myocardial localization of coronavirus in COVID-19 cardiogenic shock. *Eur. J. Heart Fail.* <https://doi.org/10.1002/ejhf.1828> (2020).
39. Xu, X. *et al.* Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci. China Life Sci.* **63**(3), 457–460. <https://doi.org/10.1007/s11427-020-1637-5> (2020).

40. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**(6483), 1260–1263. <https://doi.org/10.1126/science.abb2507> (2020).
41. South, A. M., Diz, D. I. & Chappell, M. C. COVID-19, ACE2, and the cardiovascular consequences. *Am. J. Physiol. Heart Circ. Physiol.* **318**(5), H1084–H1090. <https://doi.org/10.1152/ajpheart.00217.2020> (2020).
42. Zou, X. *et al.* Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front. Med.* <https://doi.org/10.1007/s11684-020-0754-0> (2020).
43. Liu, Y. *et al.* Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci. China Life Sci.* **63**(3), 364–374. <https://doi.org/10.1007/s11427-020-1643-8> (2020).
44. Oudit, G. Y. *et al.* SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. *Eur. J. Clin. Invest.* **39**(7), 618–625. <https://doi.org/10.1111/j.1365-2362.2009.02153.x> (2009).
45. Vaughan, D. E., Lazos, S. A. & Tong, K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. *J. Clin. Invest.* **95**(3), 995–1001. <https://doi.org/10.1172/JCI117809> (1995).

Acknowledgements

We thank Julia Esparza and Erin Ware for assistance with the literature search. We thank Georgia Morgan for her assistance editing this manuscript.

Author contributions

Study concept and design: A.S., M.M., Dominic. Literature search: A.S., M.M. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: P.D. Statistical analysis: D.D., P.D. Administrative, technical, or material support: P.D. Study supervision: P.D.

Funding

This publication was supported by an Institutional Development Award from the National Institutes of General Medical Sciences of the National Institutes of Health (NIH) under Grant Number P20GM121307 to C.G. Kevil.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-84643-6>.

Correspondence and requests for materials should be addressed to P.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021